These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 18948649)

  • 1. Immunogenicity and safety of DTPw-hepatitis B combined vaccines.
    Singh O
    Indian Pediatr; 2008 Oct; 45(10):815-6. PubMed ID: 18948649
    [No Abstract]   [Full Text] [Related]  

  • 2. Four is better than nine. a combined diphtheria-tetanus-pertussis-hepatitis B-Haemophilus influenzae type b vaccine for routine immunization in Malaysia.
    Wong SL; Soosai P; Teoh YL; Han HH; Lefevre I; Bock HL
    Southeast Asian J Trop Med Public Health; 2008 May; 39(3):474-83. PubMed ID: 18564687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of hepatitis B vaccine incorporated into the expanded program of immunization schedule.
    Gomber S; Sharma R; Ramachandran VG; Talwar V; Singh B
    Indian Pediatr; 2000 Apr; 37(4):411-3. PubMed ID: 10781235
    [No Abstract]   [Full Text] [Related]  

  • 4. Primary vaccination with a new heptavalent DTPw-HBV/Hib-Neisseria meningitidis serogroups A and C combined vaccine is well tolerated.
    Kerdpanich A; Warachit B; Kosuwon P; Gatchalian SR; Watanaveeradej V; Borkird T; Kosalaraksa P; Han HH; Hutagalung Y; Boutriau D; Dobbelaere K
    Int J Infect Dis; 2008 Jan; 12(1):88-97. PubMed ID: 17716936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Basic immunization hexvalent vaccine. Are there differences between vaccines?].
    MMW Fortschr Med; 2003 May; 145(19):54. PubMed ID: 12813984
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV).
    Knuf M; Szenborn L; Moro M; Petit C; Bermal N; Bernard L; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S97-S108. PubMed ID: 19325452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3, 4, and 12-14 months of age.
    Halperin SA; Tapiero B; Diaz-Mitoma F; Law BJ; Hoffenbach A; Zappacosta PS; Radley D; McCarson BJ; Martin JC; Brackett LE; Boslego JW; Hesley TM; Bhuyan PK; Silber JL
    Vaccine; 2009 Apr; 27(19):2540-7. PubMed ID: 19124057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A population-based, postlicensure evaluation of the safety of a combination diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine in a large managed care organization.
    Zangwill KM; Eriksen E; Lee M; Lee J; Marcy SM; Friedland LR; Weston W; Howe B; Ward JI
    Pediatrics; 2008 Dec; 122(6):e1179-85. PubMed ID: 19047220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pediarix--a combined vaccine for infants.
    Med Lett Drugs Ther; 2003 May; 45(1156):37-8. PubMed ID: 12736597
    [No Abstract]   [Full Text] [Related]  

  • 10. International prospects for combined vaccines with emphasis on quadrivalent diphtheria-tetanus-pertussis-hepatitis B vaccine.
    Melnick JL
    Ann N Y Acad Sci; 1995 May; 754():267-72. PubMed ID: 7625661
    [No Abstract]   [Full Text] [Related]  

  • 11. [Component in diphtheria-pertussis-tetanus-hepatitis B vaccine].
    Xie D; Zhang J; Gong Z; Liu B; Tang Q; Han Y; Dou Y; Zhao J
    Zhonghua Yu Fang Yi Xue Za Zhi; 1999 May; 33(3):156-7. PubMed ID: 11864474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and reactogenicity of an indigenous combined diphtheria, tetanus, whole-cell Bordetella pertussis and hepatitis B vaccine in Indian infants.
    Raghu MB; Latha R; Bhave S; Sivananda A; Pramod G; Kavita S; Arulprakash R; Bhusari P; Lad S; Raman R
    J Trop Pediatr; 2005 Aug; 51(4):261. PubMed ID: 15958410
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines.
    Chevallier B; Vesikari T; Brzostek J; Knuf M; Bermal N; Aristegui J; Borys D; Cleerbout J; Lommel P; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S109-18. PubMed ID: 19325447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hexavalent vaccines facilitate compliance. Vaccination calendars become significantly simpler].
    MMW Fortschr Med; 2002 Jan; 144(1-2):68. PubMed ID: 11847892
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunisation and the importance of good timing.
    Grant C
    N Z Med J; 2004 Aug; 117(1199):U992. PubMed ID: 15475975
    [No Abstract]   [Full Text] [Related]  

  • 16. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity.
    Bermal N; Szenborn L; Chrobot A; Alberto E; Lommel P; Gatchalian S; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S89-96. PubMed ID: 19325451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection against vaccine-preventable diseases in medical students.
    Baer G; Bonhoeffer J; Schaad UB; Heininger U
    Pediatr Infect Dis J; 2003 Apr; 22(4):373-4. PubMed ID: 12712970
    [No Abstract]   [Full Text] [Related]  

  • 18. Immunogenicity and safety of a DTaP-IPV//PRP-T vaccine (Pentaxim) booster during the second year of life in Thai children primed with an acellular pertussis combined vaccine.
    Thisyakorn U; Pancharoen C; Chuenkitmongkol S; Ortiz E
    Southeast Asian J Trop Med Public Health; 2009 Mar; 40(2):282-94. PubMed ID: 19323013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term antibody persistence in children primed and boosted with a DTPw-HBV vaccine at 2, 4, 6, 18, months of age.
    Poovorawan Y; Hutagalung Y; Chongsrisawat V; Thaemboonlers A; Lefevre I
    Vaccine; 2008 Mar; 26(12):1535-40. PubMed ID: 18289746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coverage of recommended vaccines in children at 7-8 years of age in Flanders, Belgium.
    Theeten H; Vandermeulen C; Roelants M; Hoppenbrouwers K; Depoorter AM; Van Damme P
    Acta Paediatr; 2009 Aug; 98(8):1307-12. PubMed ID: 19432835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.